Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages 57-66

  Topp, Max S ^a   Gökbuget, Nicola ^b   Stein, Anthony S ^c   Zugmaier, Gerhard ^d   O'Brien, Susan ^e   Bargou, Ralf C ^a   Dombret, Hervé ^f   Fielding, Adele K ^g   Heffner, Leonard ^h   Larson, Richard A ⁱ   Neumann, Svenja ^j   Foà, Robin ^k   Litzow, Mark ^l   Ribera, Josep Maria ^m   Rambaldi, Alessandro ⁿ   Schiller, Gary ^o   Brüggemann, Monika ^p   Horst, Heinz A ^p   Holland, Chris ^q   Jia, Catherine ^r   Maniar, Tapan ^r   Huber, Birgit ^d   Nagorsen, Dirk ^r   Forman, Stephen J ^c   Kantarjian, Hagop M ^e   more..

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d Amgen Research GmbH   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j F+E Zentrum   (Germany)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l MAYO CLINIC   (United States)

^m HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁿ Unit of Nephrology and Dialysis   (Italy)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^q Amgen   (United States)

^r AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; DEXAMETHASONE; PARACETAMOL; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; APHASIA; ARTICLE; ATAXIA; BLOOD CELL COUNT; BRADYPHRENIA; BRAIN DISEASE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTINUOUS INFUSION; CONVULSION; CYTOKINE RELEASE SYNDROME; DELIRIUM; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG FATALITY; DRUG SAFETY; DYSARTHRIA; DYSESTHESIA; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEMATOPOIETIC STEM CELL; HEMIPARESIS; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SOMNOLENCE; STUPOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; ADOLESCENT; AGE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY; TIME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84926099033     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71170-2     Document Type: Article

References (28)

1. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007, 109:944-950.
2. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012, 120:2032-2041. for the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia.
3. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010, 116:5568-5574.
4. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008, 113:3186-3191.
5. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010, 95:589-596.
6. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007, 21:1907-1914.
7. O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 2008, 113:2097-2101.
8. Campana D, Janossy G, Bofill M, et al. Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. J Immunol 1985, 134:1524-1530.
9. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011, 52:1098-1107.
10. Loffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003, 17:900-909.
11. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002, 100:690-697.
12. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005, 115:98-104.
13. Topp MS, Gökbuget N, Zugmaier G, et al. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. Proc Am Soc Clin Oncol 2012, 30:6500. (abstr).
14. Topp MS, Gökbuget N, Zugmaier G, et al. A phase II trial of the anti-CD19 BiTE blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014, published online Nov 10. 10.1200/JCO.2014.56.3247.
15. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
16. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
17. NCI common terminology criteria for adverse events (CTCAE) v4.0 2014, National Cancer Institute, National Cancer Institute, Bethesda, MD.
18. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
19. Mantel N, Byar DP Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc 1974, 69:81-86.
20. Anderson JR, Cain KC, Gelber RD Analysis of survival by tumor response. J Clin Oncol 1983, 1:710-719.
21. NCCN guidelines acute lymphoblastic leukemia v1.2013 2013, National Comprehensive Cancer Network, National Comprehensive Cancer Network, Fort Washington, PA.
22. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012, 13:403-411.
23. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013, 119:2728-2736.
24. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
25. Davila ML, Riviere I, Wang X, et al. Safe and effective re-induction of complete remissions in adults with relapsed B-ALL using 19-28z CAR CD19-targeted T cell therapy. Blood 2013, 122:69. (abstr).
26. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
27. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
28. Raff T, Gökbuget N, Luschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109:910-915.